In 2024, KingMed Diagnostics completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).
However, KingMed Diagnostics has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021-2019 |
|---|---|---|---|---|
Total Scope 1 | 5,645.67a | 5,235.95a | 7,532.43a | |
Total Scope 2 | ||||
Location-Based | 32,926.23a | 29,138.59a | 29,237.54a | |
Total Scope 3 | N/A | N/A | N/A | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 5.7309a | 4.3576a | 3.389a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2024, the total operational greenhouse gas (GHG) emissions of KingMed Diagnostics amounted to 38,571.9 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2023, the total operational greenhouse gas (GHG) emissions of KingMed Diagnostics increased by 12.21%, suggesting that the company faced challenges in reducing its emissions from its core operations.a
In 2024, the total Scope 1 emissions of KingMed Diagnostics were 5,645.67 metric tons of CO₂ equivalent (tCO₂e).a
Since 2021, KingMed Diagnostics's Scope 1 emissions have decreased by 37.39%, reflecting a declining long-term trend in Scope 1 emissions over time.ab
Compared to the previous year (2023), KingMed Diagnostics's Scope 1 emissions increased by 7.83%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.a
In 2024, KingMed Diagnostics reported Scope 2 greenhouse gas (GHG) emissions of 32,926.23 tCO₂e using the location-based method.a
Since 2021, KingMed Diagnostics's Scope 2 greenhouse gas (GHG) emissions (Location-Based) have increased by 37.68%, reflecting a rising long-term trend in Scope 2 emissions over time.ab
Compared to the previous year (2023), KingMed Diagnostics's Scope 2 emissions (Location-Based) rose by 13% in 2024, suggesting that the company faced challenges in reducing emissions from purchased electricity and energya
In 2024, KingMed Diagnostics reported its Scope 2 emissions using the location-based method.a
In 2024, KingMed Diagnostics reported Scope 1 greenhouse gas (GHG) emissions of 5,645.67 tCO₂e and total revenues of USD 985 millions. This translates into an emissions intensity of 5.73 tCO₂e per millions USD.a
In 2024, KingMed Diagnostics reported a Scope 1 emissions intensity of 5.73 tCO₂e per millions USD. Compared to the peer group median of 4.48, this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors.a
In 2024, KingMed Diagnostics ranked 17 out of 24 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
KingMed Diagnostics is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency.a